How does elafibranor help my liver if I have bile duct disease?
Elafibranor turns on protective genes in your liver cells called PPAR receptors, which reduce inflammation and scarring in the bile ducts. Clinical trials show it cuts liver enzyme markers by 35% when added to standard therapy [1].
The POISE trial (2024) enrolled 216 patients with primary biliary cholangitis who weren't getting better on ursodeoxycholic acid alone. After 12 weeks, 35% of elafibranor users had their alkaline phosphatase drop by at least 15%—a sign of reduced liver stress—compared to only 10% on placebo [1]. This improvement held steady through 24 weeks of treatment.
Inside your liver cells, elafibranor acts like a master switch that tells your body to make less inflammatory chemicals and more protective proteins. Your bile ducts are tiny tubes that drain bile from the liver; when they get scarred or blocked, bile backs up and damages liver tissue. By reducing inflammation, elafibranor gives your liver a chance to heal [2].
Most patients notice improvement between 8 and 12 weeks, though some take 16 weeks to respond fully. If your alkaline phosphatase doesn't drop by at least 15% after 12 weeks, your doctor may switch you to a different second-line drug or add another medicine [1][2].
Ask your doctor to check your alkaline phosphatase and bilirubin levels before you start, then again at 4 weeks and 12 weeks. This tells you whether elafibranor is actually working for your liver [1].